Aprea Therapeutics, Inc. (NASDAQ: APRE) completed a private placement on January 29, 2026, selling 6,288,857 shares of common stock at $0.89 per share and issuing an equal number of warrants with an exercise price of $0.765 that expire two years after the placement’s registration statement becomes effective. The transaction generated approximately $5.6 million in gross proceeds.
The company will allocate the proceeds to general corporate purposes and research and development, with a primary focus on backfilling patients in the Phase 1, open‑label, multicenter ACESOT‑1051 study of APR‑1051 in advanced solid‑tumor patients. By adding patients, Aprea aims to accelerate dose‑optimization and advance key clinical milestones for its lead DDR‑targeted therapy.
Prior to the placement, Aprea reported cash and cash equivalents of $13.7 million as of the third quarter of 2025, a balance that was expected to support operations through the fourth quarter of 2026. The company’s December 9, 2025 private placement of $3.1 million had previously extended the runway into the first quarter of 2027. The new $5.6 million infusion further extends liquidity, though the issuance of new shares and warrants will increase the share count and potentially dilute existing shareholders if the warrants are exercised.
Aprea’s oncology portfolio centers on DNA‑damage‑response (DDR) pathways, with APR‑1051, a WEE1 inhibitor, and ATRN‑119, an ATR inhibitor, as its lead candidates. The ACESOT‑1051 trial has already reported an unconfirmed partial response in an endometrial‑cancer patient, underscoring the therapeutic promise of APR‑1051 and justifying the additional investment to expedite dose‑finding and safety data.
CEO Oren Gilad emphasized that the financing will “enable proactive patient backfilling in the ACESOT‑1051 study, potentially accelerating dose‑optimization and clinical milestones.” The capital raise positions Aprea to maintain momentum in its precision‑oncology pipeline while addressing the company’s cash runway concerns, a critical factor for a clinical‑stage biopharmaceutical with no revenue streams.
Overall, the private placement strengthens Aprea’s financial foundation, supports the advancement of its DDR‑targeted therapies, and signals management’s confidence in the company’s clinical strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.